CD274 and breast carcinoma: The data available in patients with HR+/HER2− breast cancer is limited, with the KEYNOTE-028 trial of patients with estrogen receptor-positive/HER2- advanced breast cancer and PD-L1 + tumors showing a median progression free survival of 1.8 months and an objective response rate of 12%35.